دورية أكاديمية
Extended Adjuvant Endocrine Treatment in Luminal Breast Cancers in the Era of Genomic Tests
| العنوان: | Extended Adjuvant Endocrine Treatment in Luminal Breast Cancers in the Era of Genomic Tests |
|---|---|
| المؤلفون: | Saponaro M., Annunziata L., Turla A., Vigano I., De Laurentiis M., Giuliano M., Del Mastro L., Montemurro F., Puglisi F., De Angelis C., Buono G., Schettini F., Arpino G. |
| المساهمون: | Saponaro, M., Annunziata, L., Turla, A., Vigano, I., De Laurentiis, M., Giuliano, M., Del Mastro, L., Montemurro, F., Puglisi, F., De Angelis, C., Buono, G., Schettini, F., Arpino, G. |
| سنة النشر: | 2022 |
| المجموعة: | Università degli Studi di Udine: CINECA IRIS |
| مصطلحات موضوعية: | clinical score, extended endocrine therapy, genomic assay, hormone receptor-positive breast cancer, late recurrence |
| الوصف: | In patients with early-stage endocrine receptor-positive (ER+) breast cancer (BC), adjuvant endocrine therapy (ET) for 5 years is the standard of care. However, for some patients, the risk of recurrence remain high for up to 15 years after diagnosis and extended ET beyond 5 years may be a reasonable option. Nevertheless, this strategy significantly increases the occurrence of side effects. Here we summarize the available evidence from randomized clinical trials on the efficacy and safety profile of extended ET and discuss available clinical and genomic tools helpful to select eligible patients in daily clinical practice. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | volume:23; issue:21; firstpage:13604; journal:INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES; https://hdl.handle.net/11390/1238131Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85141614351 |
| DOI: | 10.3390/ijms232113604 |
| الإتاحة: | https://doi.org/10.3390/ijms232113604Test https://hdl.handle.net/11390/1238131Test |
| حقوق: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.214C2B7E |
| قاعدة البيانات: | BASE |
| DOI: | 10.3390/ijms232113604 |
|---|